Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Capmatinib is an oral MET inhibitor that received Breakthrough Therapy Designation, Orphan Drug Designation, Accelerated Approval, and Priority Review from the United States FDA fo···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：309
Capmatinib is a targeted drug used to treat a specific type of non-small cell lung cancer (NSCLC). It is a MET inhibitor with good efficacy in lung cancer patients with MET gene mu···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：331
Capmatinib acts as a targeted therapy to stop the growth and spread of cancer cells by inhibiting MET tyrosine kinase activity. Usually, this medication is for those who do not res···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：318
Exkivity is a targeted drug for the treatment of specific types of non-small cell lung cancer (NSCLC), particularly in patients with epidermal growth factor receptor (EGFR) exon 20···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：270
Exkivity is an oral capsule drug primarily used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR exon 20 inse···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：307
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) primarily used for the treatment of adult patients with locally advanced or metastatic non-small cel···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：273
Exkivity offers a new treatment option for NSCLC patients with EGFR exon 20 insertion mutations but should be used with caution and in accordance with professional medical advice.W···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：256
Capmatinib is a targeted drug manufactured by Novartis for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：304
Exkivity provides a new treatment option for NSCLC patients with EGFR exon 20 insertion mutations, with significant efficacy and a favorable safety profile.What diseases is Exkivit···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：232
Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells by inhibiting MET phosphorylation triggered by hepatocyte growth factor binding or MET amplificatio···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：212
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) primarily for the treatment of adult patients with locally advanced or metastatic non-small cell lun···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：218
Capmatinib is highly selective for c-Met targets, can effectively inhibit the proliferation and migration of c-Met-dependent tumor cells, and can effectively induce apoptosis to ac···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：250
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2262025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2322025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2452025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2252025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2532025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2352025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2162025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
